Shayan Mohammadmoradi/LinkedIn
Nov 7, 2026, 08:28
Shayan Mohammadmoradi: Targeting Inflammation in Atherosclerosis
Shayan Mohammadmoradi, Vascular Biology and Platelet Function Scientist at University of Kentucky, CEO at Moradi Enterprise, shared a post on LinkedIn:
“Strong opener at Scientific Sessions 26 on targeting inflammation in atherosclerosis: efferocytosis, resolution, tRNA-derived small RNAs, macrophage genomics, and Dr. Paul Ridker on where anti-inflammatory therapy goes next.
Thanks Yabing Chen and Katey Rayner for moderating!”
Other posts featuring Shayan Mohammadmoradi on Hemostasis Today.
-
Nov 7, 2026, 08:15Abdul Mannan: Severe Coagulopathy and the Importance of Drug History
-
Nov 7, 2026, 07:59Zahra Ghasemi: Plasma Self-Sufficiency – Are We Measuring Supply or Actual Need?
-
Nov 7, 2026, 06:11Bruno Matos Santos: Gastric and Oesophageal Necrosis Due to Extensive Venous Thrombosis
-
Nov 7, 2026, 05:57Nawsherwan Mohammad: Hypercoagulability and Pulmonary Hypertension in Beta Thalassemia
-
Nov 7, 2026, 05:45Andrew Davies: HIDDEN 2 Rethinking Thromboprophylaxis in Hospice Care
-
Nov 7, 2026, 05:32Cancer, Catheters and Outcomes in Upper Extremity DVT – JTH
-
Nov 7, 2026, 02:57Abdelghani Mazouzi: SMIM1 Links Hemoglobin Internalization to Cellular Iron Metabolism
-
Nov 7, 2026, 02:34Ali Moradi: Two Network Meta-Analyses on Cardiovascular Therapies to Be Presented at AHA 2026
-
Nov 7, 2026, 02:21Amit Mohan: Microfluidic Technology Advances the Assessment of Biomaterial-Induced Thrombosis